nemolizumab   Click here for help

GtoPdb Ligand ID: 8720

Synonyms: CD14152 | CIM 331 | CIM331 | Mitchga®
Approved drug Immunopharmacology Ligand
nemolizumab is an approved drug (Japan (2022))
Compound class: Antibody
Comment: Nemolizumab is an investigational monoclonal targeting the α subunit of the IL-31 receptor. Nemolizumab has been designed for treating or preventing inflammatory diseases [3].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
BLAST peptide analysis of patented peptide sequences reveals that the heavy and light variable domains of nemolizumab are identical to SEQ ID NO: 210 and SEQ ID NO: 220 respectively, in patent US8575317 B2 [4]. This combination of peptides corresponds to one of the preferred antibodies, designated as H44L17 therein.
Click here for help
No information available.
Summary of Clinical Use Click here for help
A Phase 1 safety, tolerability and PK study detected no serious adverse events in any of the trial subjects, and nemolizumab reduced pruritus and use of hydrocortisone in patients with atopic dermatitis (AD) [5]. Nemolizumab was advanced to Phase 2 & 3 clinical evaluations [1-2]. First approval was granted in Japan (March 2022) for the treament of unresolved itch associated with AD.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03989206 Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis Phase 3 Interventional Galderma R&D
NCT04204616 A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) Phase 3 Interventional Galderma R&D